Potent intermediate conductance Ca2+-activated K+ channel (KCa3.1) blocker (Kd = 60 nM). Has no effect on cytochrome p450 activity. Inhibits I-EBIO-stimulated increases in rat artery membrane potential ex vivo. Also diminishes LPS-induced cryptidin (mammalian α-defensin) release from paneth cells in vitro.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 303.78. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.5 mM||6.58 mL||32.92 mL||65.84 mL|
|2.5 mM||1.32 mL||6.58 mL||13.17 mL|
|5 mM||0.66 mL||3.29 mL||6.58 mL|
|25 mM||0.13 mL||0.66 mL||1.32 mL|
References are publications that support the biological activity of the product.
Wulff et al (2000) Design of a potent and selective inhibitor of the intermediate-conductance Ca2+-activated K+ channel, IKCa1: a potential immunosuppressant. Proc.Natl.Acad.Sci.U.S.A. 97 8151 PMID: 10884437
Burnham et al (2006) Impaired small-conductance Ca2+-activated K+ channel-dependent EDHF responses in Type II diabetic ZDF rats. Br.J.Pharmacol. 148 434 PMID: 16682967
Ayabe et al (2002) Modulation of mouse Paneth cell alpha-defensin secretion by mIKCa1, a Ca2+-activated, intermediate conductance potassium channel. J.Biol.Chem. 277 3793 PMID: 11724775
If you know of a relevant reference for TRAM 39, please let us know.
View Related Products by Product Action
Keywords: TRAM 39, TRAM 39 supplier, TRAM39, potent, intermediate, conductance, calcium, Ca2+, actiavted, potassium, K+, channels, blockers, blocks, KCa3.1, IKCa1, ion, Ca2+-Activated, Potassium, Channels, 4952, Tocris Bioscience
Citations for TRAM 39
Citations are publications that use Tocris products.
Currently there are no citations for TRAM 39. Do you know of a great paper that uses TRAM 39 from Tocris? Please let us know.
Reviews for TRAM 39
There are currently no reviews for this product. Be the first to review TRAM 39 and earn rewards!
Have you used TRAM 39?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.